title: Chronic effects of centrally administered adiponectin on appetite, metabolism and blood pressure regulation in normotensive and hypertensive rats.
abstract: Acute studies suggest that adiponectin may reduce sympathetic activity and blood pressure (BP) via actions on the central nervous system (CNS). However, the chronic effects of adiponectin on energy expenditure and cardiovascular function are still poorly understood. We tested if chronic intracerebroventricular (ICV) infusion of adiponectin (1 or 7μg/day) in Sprague-Dawley rats fed a high fat diet (HFD) for 8 weeks and at the high dose (7μg/day) in spontaneously hypertensive rats (SHRs), a hypertensive model associated with sympathetic overactivity, evoked chronic reductions in BP and heart rate (HR). We also determined if chronic ICV adiponectin infusion alters appetite, whole body oxygen consumption (VO(2)), and insulin and leptin levels. Neither dose of adiponectin infused for 7 days significantly altered BP or HR in the HFD group (115±2 to 112±2mmHg and 384±6 to 379±6bpm at 1μg/day; 109±3 to 111±3mmHg and 366±5 and 367±5bpm at 7μg/day). The higher dose slightly reduced food intake (14±1 to 11±1g/day), whereas VO(2), insulin and leptin levels were not affected by the treatment. In SHRs, ICV adiponectin infusion reduced appetite (22±2 to 12±2g/day) and insulin levels (∼55%), but did not alter BP (162±4 to 164±3mmHg) or HR (312±5 to 322±8bpm). These results suggest that adiponectin, acting via its direct actions on the CNS, has a small effect to reduce appetite and insulin levels, but it has no long-term action to reduce BP or HR, or to alter whole body metabolic rate.
authors: Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA.
authors: Mirian
authors: M
authors: Bassi
authors: Jussara M
authors: JM
authors: do Carmo
authors: John E
authors: JE
authors: Hall
authors: Alexandre A
authors: AA
authors: da Silva
mesh_terms: D052242:Adiponectin / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001066:Appetite / Q000187:drug effects*; D001786:Blood Glucose; D001794:Blood Pressure / Q000187:drug effects*; D059305:Diet, High-Fat / Q000009:adverse effects; D005632:Fructose / Q000009:adverse effects; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D057967:Infusions, Intraventricular; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D051381:Rats; D011918:Rats, Inbred SHR; D017207:Rats, Sprague-Dawley
chemical_list: D052242:Adiponectin; D000959:Antihypertensive Agents; D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D005632:Fructose